NEW YORK – Epigenetic markers can distinguish between individuals with type 2 diabetes who respond to metformin treatment and those who do not, a new study has found.
Metformin is commonly prescribed to individuals with type 2 diabetes, but about 30 percent of patients don't respond to the drug and between 20 percent and 30 percent experience side effects that can be intolerable.